These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20144324)

  • 1. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99).
    Urdea M; Kolberg J; Wilber J; Gerwien R; Moler E; Rowe M; Jorgensen P; Hansen T; Pedersen O; Jørgensen T; Borch-Johnsen K
    J Diabetes Sci Technol; 2009 Jul; 3(4):748-55. PubMed ID: 20144324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.
    Kolberg JA; Jørgensen T; Gerwien RW; Hamren S; McKenna MP; Moler E; Rowe MW; Urdea MS; Xu XM; Hansen T; Pedersen O; Borch-Johnsen K
    Diabetes Care; 2009 Jul; 32(7):1207-12. PubMed ID: 19564473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a multi-marker model for the prediction of incident type 2 diabetes mellitus: combined results of the Inter99 and Botnia studies.
    Lyssenko V; Jørgensen T; Gerwien RW; Hansen T; Rowe MW; McKenna MP; Kolberg J; Pedersen O; Borch-Johnsen K; Groop L
    Diab Vasc Dis Res; 2012 Jan; 9(1):59-67. PubMed ID: 22058089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort.
    Shafizadeh TB; Moler EJ; Kolberg JA; Nguyen UT; Hansen T; Jorgensen T; Pedersen O; Borch-Johnsen K
    PLoS One; 2011; 6(7):e22863. PubMed ID: 21829540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx ® Diabetes Risk Score.
    Kolberg JA; Gerwien RW; Watkins SM; Wuestehube LJ; Urdea M
    Expert Rev Mol Diagn; 2011 Nov; 11(8):775-92. PubMed ID: 22022939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies.
    Soulimane S; Simon D; Shaw JE; Zimmet PZ; Vol S; Vistisen D; Magliano DJ; Borch-Johnsen K; Balkau B
    Diabet Med; 2011 Nov; 28(11):1311-8. PubMed ID: 21824186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and metabolomic predictors of regression to normoglycemia in a population at intermediate cardiometabolic risk.
    Sevilla-González MDR; Merino J; Moreno-Macias H; Rojas-Martínez R; Gómez-Velasco DV; Manning AK
    Cardiovasc Diabetol; 2021 Feb; 20(1):56. PubMed ID: 33639941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R.
    Soulimane S; Simon D; Shaw J; Witte D; Zimmet P; Vol S; Borch-Johnsen K; Magliano D; Vistisen D; Balkau B
    Diabetes Res Clin Pract; 2012 Jun; 96(3):392-9. PubMed ID: 21741107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study.
    Hippisley-Cox J; Coupland C
    BMJ; 2017 Nov; 359():j5019. PubMed ID: 29158232
    [No Abstract]   [Full Text] [Related]  

  • 10. [Validation of the German Diabetes Risk Score with metabolic risk factors for type 2 diabetes].
    Schulze MB; Boeing H; Häring HU; Fritsche A; Joost HG
    Dtsch Med Wochenschr; 2008 Apr; 133(17):878-83. PubMed ID: 18415912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score.
    Sullivan SD; Garrison LP; Rinde H; Kolberg J; Moler EJ
    J Med Econ; 2011; 14(5):609-16. PubMed ID: 21740291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early metabolic markers identify potential targets for the prevention of type 2 diabetes.
    Peddinti G; Cobb J; Yengo L; Froguel P; Kravić J; Balkau B; Tuomi T; Aittokallio T; Groop L
    Diabetologia; 2017 Sep; 60(9):1740-1750. PubMed ID: 28597074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study.
    Franciosi M; De Berardis G; Rossi MC; Sacco M; Belfiglio M; Pellegrini F; Tognoni G; Valentini M; Nicolucci A
    Diabetes Care; 2005 May; 28(5):1187-94. PubMed ID: 15855587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma metabolites associated with type 2 diabetes in a Swedish population: a case-control study nested in a prospective cohort.
    Shi L; Brunius C; Lehtonen M; Auriola S; Bergdahl IA; Rolandsson O; Hanhineva K; Landberg R
    Diabetologia; 2018 Apr; 61(4):849-861. PubMed ID: 29349498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a multi-marker diabetes risk score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort.
    Rowe MW; Bergman RN; Wagenknecht LE; Kolberg JA
    Diabetes Metab Res Rev; 2012 Sep; 28(6):519-26. PubMed ID: 22492485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study.
    Engberg S; Vistisen D; Lau C; Glümer C; Jørgensen T; Pedersen O; Borch-Johnsen K
    Diabetes Care; 2009 Apr; 32(4):606-11. PubMed ID: 19114617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes.
    Khan SR; Mohan H; Liu Y; Batchuluun B; Gohil H; Al Rijjal D; Manialawy Y; Cox BJ; Gunderson EP; Wheeler MB
    Diabetologia; 2019 Apr; 62(4):687-703. PubMed ID: 30645667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
    Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential relationship between physical activity and progression to diabetes by glucose tolerance status: the Inter99 Study.
    Engberg S; Glümer C; Witte DR; Jørgensen T; Borch-Johnsen K
    Diabetologia; 2010 Jan; 53(1):70-8. PubMed ID: 19898830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
    Pareek M
    Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.